{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:20:28Z","timestamp":1789730428301,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0275"],"award-info":[{"award-number":["W81XWH-18-1-0275"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Abnormal metabolism and perturbations in metabolic pathways play significant roles in the development and progression of prostate cancer; however, comprehensive metabolomic analyses of human data are lacking and needed to elucidate the interrelationships.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined the serum metabolome in relation to prostate cancer survival in a cohort of 1812 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Using an ultrahigh-performance LC-MS\/MS platform, we identified 961 known metabolites in prospectively collected serum. Median survival time from diagnosis to prostate cancer-specific death (<jats:italic>N<\/jats:italic>=472) was 6.6 years (interquartile range=2.9\u201311.1 years). Cox proportional hazards regression models estimated hazard ratios and 95% confidence intervals of the associations between the serum metabolites (in quartiles) and prostate cancer death, adjusted for age at baseline and diagnosis, disease stage, and Gleason sum. In order to calculate risk scores, we first randomly divided the metabolomic data into a discovery set (70%) and validated in a replication set (30%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 49 metabolites were associated with prostate cancer survival after Bonferroni correction. Notably, higher levels of the phospholipid choline, amino acid glutamate, long-chain polyunsaturated fatty acid (n6) arachidonate (20:4n6), and glutamyl amino acids gamma-glutamylglutamate, gamma-glutamylglycine, and gamma-glutamylleucine were associated with increased risk of prostate cancer-specific mortality (fourth versus first quartile HRs=2.07\u20132.14; <jats:italic>P<\/jats:italic>-values &lt;5.2\u00d710<jats:sup>\u22125<\/jats:sup>). By contrast, the ascorbate\/aldarate metabolite oxalate, xenobiotics S-carboxymethyl-L-cysteine, fibrinogen cleavage peptides ADpSGEGDFXAEGGGVR and fibrinopeptide B (1-12) were related to reduced disease-specific mortality (fourth versus first quartile HRs=0.82\u20130.84; <jats:italic>P<\/jats:italic>-value &lt;5.2\u00d710<jats:sup>\u22125<\/jats:sup>). Further adjustment for years from blood collection to cancer diagnosis, body mass index, smoking intensity and duration, and serum total and high-density lipoprotein cholesterol did not alter the results. Participants with a higher metabolic score based on the discovery set had an elevated risk of prostate cancer-specific mortality in the replication set (fourth versus first quartile, HR=3.9, <jats:italic>P<\/jats:italic>-value for trend&lt;0.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The metabolic traits identified in this study, including for choline, glutamate, arachidonate, gamma-glutamyl amino acids, fibrinopeptides, and endocannabinoid and redox pathways and their composite risk score, corroborate our previous analysis of fatal prostate cancer and provide novel insights and potential leads regarding the molecular basis of prostate cancer progression and mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02561-4","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:03:25Z","timestamp":1666656205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiaqi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Albanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Mondul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"3","key":"2561_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2561_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djaa154","volume":"113","author":"LM Hurwitz","year":"2021","unstructured":"Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, et al. Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. J Natl Cancer Inst. 2021;113(6):727\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"127","key":"2561_CR3","doi-asserted-by":"publisher","first-page":"127rv123","DOI":"10.1126\/scitranslmed.3003180","volume":"4","author":"JR Prensner","year":"2012","unstructured":"Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv123.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2561_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/jcb.10700","volume":"91","author":"EA Platz","year":"2004","unstructured":"Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem. 2004;91(3):553\u201371.","journal-title":"J Cell Biochem"},{"issue":"9","key":"2561_CR5","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.3390\/ijms22094367","volume":"22","author":"S Salciccia","year":"2021","unstructured":"Salciccia S, Capriotti AL, Lagana A, Fais S, Logozzi M, De Berardinis E, et al. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int J Mol Sci. 2021;22(9):4367.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2561_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1055-9965.EPI-15-1223","volume":"25","author":"RS Kelly","year":"2016","unstructured":"Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev. 2016;25(6):887\u2013906.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2561_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/msb.2011.57","volume":"7","author":"G Nicholson","year":"2011","unstructured":"Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol. 2011;7:525.","journal-title":"Mol Syst Biol"},{"issue":"7","key":"2561_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/metabo9070145","volume":"9","author":"MC Playdon","year":"2019","unstructured":"Playdon MC, Joshi AD, Tabung FK, Cheng S, Henglin M, Kim A, et al. Metabolomics Analytics Workflow for Epidemiological Research: Perspectives from the Consortium of Metabolomics Studies (COMETS). Metabolites. 2019;9(7):145.","journal-title":"Metabolites"},{"issue":"1","key":"2561_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1039\/B906712B","volume":"40","author":"WB Dunn","year":"2011","unstructured":"Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2011;40(1):387\u2013426.","journal-title":"Chem Soc Rev"},{"issue":"9","key":"2561_CR10","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/ijc.29576","volume":"137","author":"AM Mondul","year":"2015","unstructured":"Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer. 2015;137(9):2124\u201332.","journal-title":"Int J Cancer"},{"issue":"1","key":"2561_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-020-01655-1","volume":"18","author":"HE Rohnisch","year":"2020","unstructured":"Rohnisch HE, Kyro C, Olsen A, Thysell E, Hallmans G, Moazzami AA. Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study. BMC Med. 2020;18(1):187.","journal-title":"BMC Med"},{"issue":"9","key":"2561_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/bjc.2016.305","volume":"115","author":"J Huang","year":"2016","unstructured":"Huang J, Mondul AM, Weinstein SJ, Koutros S, Derkach A, Karoly E, et al. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Br J Cancer. 2016;115(9):1087\u201395.","journal-title":"Br J Cancer"},{"issue":"12","key":"2561_CR13","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/ijc.32218","volume":"145","author":"J Huang","year":"2019","unstructured":"Huang J, Mondul AM, Weinstein SJ, Derkach A, Moore SC, Sampson JN, et al. Prospective serum metabolomic profiling of lethal prostate cancer. Int J Cancer. 2019;145(12):3231\u201343.","journal-title":"Int J Cancer"},{"issue":"1","key":"2561_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12916-017-0885-6","volume":"15","author":"JA Schmidt","year":"2017","unstructured":"Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Med. 2017;15(1):122.","journal-title":"BMC Med"},{"key":"2561_CR15","doi-asserted-by":"publisher","first-page":"338381","DOI":"10.1016\/j.aca.2021.338381","volume":"1158","author":"A Cerrato","year":"2021","unstructured":"Cerrato A, Bedia C, Capriotti AL, Cavaliere C, Gentile V, Maggi M, et al. Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine. Anal Chim Acta. 2021;1158:338381.","journal-title":"Anal Chim Acta"},{"issue":"3","key":"2561_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/metabo11030181","volume":"11","author":"AR Lima","year":"2021","unstructured":"Lima AR, Pinto J, Amaro F, Bastos ML, Carvalho M, Guedes de Pinho P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites. 2021;11(3):181.","journal-title":"Metabolites"},{"issue":"6","key":"2561_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/gerona\/gly128","volume":"74","author":"J Huang","year":"2019","unstructured":"Huang J, Weinstein SJ, Moore SC, Derkach A, Hua X, Mondul AM, et al. Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival. J Gerontol A Biol Sci Med Sci. 2019;74(6):853\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6973","key":"2561_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","volume":"310","author":"JM Bland","year":"1995","unstructured":"Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.","journal-title":"BMJ"},{"issue":"3","key":"2561_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"key":"2561_CR20","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511802843","volume-title":"Bootstrap Methods and Their Application. Cambridge University Press","author":"AC Davison","year":"1997","unstructured":"Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge University Press; 1997."},{"issue":"3","key":"2561_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/gepi.21791","volume":"38","author":"H Chen","year":"2014","unstructured":"Chen H, Lumley T, Brody J, Heard-Costa NL, Fox CS, Cupples LA, et al. Sequence kernel association test for survival traits. Genet Epidemiol. 2014;38(3):191\u20137.","journal-title":"Genet Epidemiol"},{"issue":"12","key":"2561_CR22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc3162","volume":"11","author":"K Glunde","year":"2011","unstructured":"Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835\u201348.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2561_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3945\/ajcn.112.039784","volume":"96","author":"EL Richman","year":"2012","unstructured":"Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, et al. Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr. 2012;96(4):855\u201363.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2561_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1055-9965.EPI-16-0948","volume":"26","author":"KA Guertin","year":"2017","unstructured":"Guertin KA, Li XS, Graubard BI, Albanes D, Weinstein SJ, Goedert JJ, et al. Serum Trimethylamine N-oxide, Carnitine, Choline, and Betaine in Relation to Colorectal Cancer Risk in the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev. 2017;26(6):945\u201352.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"21","key":"2561_CR25","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1158\/1078-0432.CCR-12-1308","volume":"18","author":"S Koochekpour","year":"2012","unstructured":"Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012;18(21):5888\u2013901.","journal-title":"Clin Cancer Res"},{"key":"2561_CR26","doi-asserted-by":"publisher","first-page":"8380","DOI":"10.1038\/srep08380","volume":"5","author":"J Fazzari","year":"2015","unstructured":"Fazzari J, Lin H, Murphy C, Ungard R, Singh G. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015;5:8380.","journal-title":"Sci Rep"},{"issue":"3","key":"2561_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/jcp.21366","volume":"215","author":"M Lo","year":"2008","unstructured":"Lo M, Wang YZ, Gout PW. The x(c)- cystine\/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593\u2013602.","journal-title":"J Cell Physiol"},{"issue":"19","key":"2561_CR28","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1073\/pnas.1919250117","volume":"117","author":"A Nilsson","year":"2020","unstructured":"Nilsson A, Haanstra JR, Engqvist M, Gerding A, Bakker BM, Klingmuller U, et al. Quantitative analysis of amino acid metabolism in liver cancer links glutamate excretion to nucleotide synthesis. Proc Natl Acad Sci U S A. 2020;117(19):10294\u2013304.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"32","key":"2561_CR29","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1038\/onc.2014.352","volume":"34","author":"L Martin","year":"2015","unstructured":"Martin L, Gardner LB. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine\/glutamate exchanger SLC7A11. Oncogene. 2015;34(32):4211\u20138.","journal-title":"Oncogene"},{"issue":"3","key":"2561_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bjc.2013.323","volume":"109","author":"C Grimm","year":"2013","unstructured":"Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, et al. Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer. Br J Cancer. 2013;109(3):610\u20134.","journal-title":"Br J Cancer"},{"issue":"9","key":"2561_CR31","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1541-7786.MCR-18-1204","volume":"17","author":"A Bansal","year":"2019","unstructured":"Bansal A, Sanchez DJ, Nimgaonkar V, Sanchez D, Riscal R, Skuli N, et al. Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression. Mol Cancer Res. 2019;17(9):1881\u201392.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2561_CR32","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ijc.30511","volume":"140","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of prostate cancer: Findings from the KIHD prospective cohort study. Int J Cancer. 2017;140(4):818\u201324.","journal-title":"Int J Cancer"},{"issue":"3","key":"2561_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/ijms21030747","volume":"21","author":"C Laezza","year":"2020","unstructured":"Laezza C, Pagano C, Navarra G, Pastorino O, Proto MC, Fiore D, et al. The Endocannabinoid System: a target for cancer treatment. Int J Mol Sci. 2020;21(3):747. https:\/\/doi.org\/10.3390\/ijms21030747.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2561_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrurol.2011.130","volume":"8","author":"I Diaz-Laviada","year":"2011","unstructured":"Diaz-Laviada I. The endocannabinoid system in prostate cancer. Nat Rev Urol. 2011;8(10):553\u201361.","journal-title":"Nat Rev Urol"},{"key":"2561_CR35","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of Amino Acids in Cancer. Front Cell Dev Biol. 2020;8:603837.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2561_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","volume":"17","author":"DA Bader","year":"2020","unstructured":"Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol. 2020;17(4):214\u201331.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2561_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42255-020-00329-9","volume":"3","author":"SL Geeraerts","year":"2021","unstructured":"Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR. The ins and outs of serine and glycine metabolism in cancer. Nat Metab. 2021;3(2):131\u201341.","journal-title":"Nat Metab"},{"issue":"4","key":"2561_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","volume":"39","author":"I Amelio","year":"2014","unstructured":"Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"2561_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"2-3","key":"2561_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10555-018-9750-0","volume":"37","author":"AA Panagiotopoulos","year":"2018","unstructured":"Panagiotopoulos AA, Kalyvianaki K, Castanas E, Kampa M. Eicosanoids in prostate cancer. Cancer Metastasis Rev. 2018;37(2-3):237\u201343.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2561_CR41","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.21873\/anticanres.11436","volume":"37","author":"D Separovic","year":"2017","unstructured":"Separovic D, Shields AF, Philip PA, Bielawski J, Bielawska A, Pierce JS, et al. Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. Anticancer Res. 2017;37(3):1213\u20138.","journal-title":"Anticancer Res"},{"key":"2561_CR42","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3389\/fonc.2020.01759","volume":"10","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Tie C, Wang Y, Bian D, Liu M, Wang T, et al. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. Front Oncol. 2020;10:1759.","journal-title":"Front Oncol"},{"issue":"1","key":"2561_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33\u201350.","journal-title":"Nat Rev Cancer"},{"key":"2561_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3389\/fonc.2020.00833","volume":"10","author":"A Kroll","year":"2020","unstructured":"Kroll A, Cho HE, Kang MH. Antineoplastic Agents Targeting Sphingolipid Pathways. Front Oncol. 2020;10:833.","journal-title":"Front Oncol"},{"key":"2561_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/nu12030684","volume":"12","author":"D Wanders","year":"2020","unstructured":"Wanders D, Hobson K, Ji X. Methionine Restriction and Cancer Biology. Nutrients. 2020;12:3.","journal-title":"Nutrients"},{"issue":"23","key":"2561_CR46","doi-asserted-by":"publisher","first-page":"13000","DOI":"10.1073\/pnas.1917362117","volume":"117","author":"WC Lu","year":"2020","unstructured":"Lu WC, Saha A, Yan W, Garrison K, Lamb C, Pandey R, et al. Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proc Natl Acad Sci U S A. 2020;117(23):13000\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"2561_CR47","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1038\/onc.2016.37","volume":"35","author":"MD Patil","year":"2016","unstructured":"Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene. 2016;35(38):4957\u201372.","journal-title":"Oncogene"},{"key":"2561_CR48","first-page":"14","volume":"13","author":"CL Chen","year":"2021","unstructured":"Chen CL, Hsu SC, Ann DK, Yen Y, Kung HJ. Arginine Signaling and Cancer Metabolism. Cancers (Basel). 2021;13:14.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2561_CR49","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1593\/neo.09334","volume":"11","author":"UP Kelavkar","year":"2009","unstructured":"Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A. Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia. 2009;11(7):692\u20139.","journal-title":"Neoplasia"},{"issue":"11","key":"2561_CR50","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1093\/carcin\/22.11.1765","volume":"22","author":"UP Kelavkar","year":"2001","unstructured":"Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 2001;22(11):1765\u201373.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2561_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1055-9965.EPI-18-0392","volume":"28","author":"M Hada","year":"2019","unstructured":"Hada M, Edin ML, Hartge P, Lih FB, Wentzensen N, Zeldin DC, et al. Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2019;28(1):189\u201397.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2561_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.","journal-title":"Mol Cancer"},{"issue":"3","key":"2561_CR53","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7150\/jca.46379","volume":"12","author":"Q Wu","year":"2021","unstructured":"Wu Q, Xie X, Huang Y, Meng S, Li Y, Wang H, et al. N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer. J Cancer. 2021;12(3):682\u201392.","journal-title":"J Cancer"},{"issue":"14","key":"2561_CR54","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.18632\/aging.103549","volume":"12","author":"G Ji","year":"2020","unstructured":"Ji G, Huang C, He S, Gong Y, Song G, Li X, et al. Comprehensive analysis of m6A regulators prognostic value in prostate cancer. Aging (Albany NY). 2020;12(14):14863\u201384.","journal-title":"Aging (Albany NY)"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02561-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:03:29Z","timestamp":1666656209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02561-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2561"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02561-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"3 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by institutional review boards from both the Finnish National Institute for Health and Welfare and the U.S. National Cancer Institute (reference ID: OH95CN012). Written informed consent was provided by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}